WO2006037495A3 - Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 3, group c, member 2 (nr3c2) - Google Patents

Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 3, group c, member 2 (nr3c2) Download PDF

Info

Publication number
WO2006037495A3
WO2006037495A3 PCT/EP2005/010358 EP2005010358W WO2006037495A3 WO 2006037495 A3 WO2006037495 A3 WO 2006037495A3 EP 2005010358 W EP2005010358 W EP 2005010358W WO 2006037495 A3 WO2006037495 A3 WO 2006037495A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
nr3c2
therapeutics
diagnostics
group
Prior art date
Application number
PCT/EP2005/010358
Other languages
French (fr)
Other versions
WO2006037495A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006037495A2 publication Critical patent/WO2006037495A2/en
Publication of WO2006037495A3 publication Critical patent/WO2006037495A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors

Abstract

The invention provides a human NR3C2 which is associated with the cardiovascular diseases, infections, cancer, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, cancer, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, muscle skeleton diseases, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NR3C2 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/010358 2004-10-08 2005-09-24 Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 3, group c, member 2 (nr3c2) WO2006037495A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04023997 2004-10-08
EP04023997.2 2004-10-08

Publications (2)

Publication Number Publication Date
WO2006037495A2 WO2006037495A2 (en) 2006-04-13
WO2006037495A3 true WO2006037495A3 (en) 2006-07-13

Family

ID=35911136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/010358 WO2006037495A2 (en) 2004-10-08 2005-09-24 Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 3, group c, member 2 (nr3c2)

Country Status (1)

Country Link
WO (1) WO2006037495A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
WO2006002349A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006020598A2 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
WO2006002349A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006020598A2 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HU XIAO ET AL: "Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.", MINI REVIEWS IN MEDICINAL CHEMISTRY. AUG 2005, vol. 5, no. 8, August 2005 (2005-08-01), pages 709 - 718, XP009063044, ISSN: 1389-5575 *
ZENNARO M C ET AL: "Tissue-specific expression of alpha and beta messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. MAY 1997, vol. 82, no. 5, May 1997 (1997-05-01), pages 1345 - 1352, XP002371345, ISSN: 0021-972X *

Also Published As

Publication number Publication date
WO2006037495A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
WO2006027147A3 (en) Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2006005469A3 (en) Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
WO2005100990A3 (en) Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2)
WO2005103684A3 (en) Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1)
WO2005106491A3 (en) Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2006021343A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a)
WO2005076007A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y12 (p2y12)
WO2005101001A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor, family c, group 5, member c (gprc5c)
WO2005113786A3 (en) Diagnostics and therapeutics for diseases associated with chymase (cma1)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2005073729A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor p2y11 (p2y11)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005113788A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor kinase 6 (grk6)
WO2006005460A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 2, group e, member 1 (nr2e1)
WO2006005470A3 (en) Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge)
WO2006037495A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 3, group c, member 2 (nr3c2)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005119263A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92)
WO2006005461A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 27 (gpr27)
WO2005075990A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a2 (nr4a2)
WO2005101009A3 (en) Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2)
WO2005075983A3 (en) Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a3 (nr4a3)
WO2005114205A3 (en) Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group b, member 2 (nr1b2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase